image
Healthcare - Biotechnology - NASDAQ - NL
$ 11.4014
10.9 %
$ 3.18 B
Market Cap
None
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one NAMSW stock under the worst case scenario is HIDDEN Compared to the current market price of 11.4 USD, NewAmsterdam Pharma Company N.V. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one NAMSW stock under the base case scenario is HIDDEN Compared to the current market price of 11.4 USD, NewAmsterdam Pharma Company N.V. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one NAMSW stock under the best case scenario is HIDDEN Compared to the current market price of 11.4 USD, NewAmsterdam Pharma Company N.V. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NAMSW

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
45.6 M REVENUE
257.00%
-176 M OPERATING INCOME
-6.37%
-242 M NET INCOME
-36.54%
-159 M OPERATING CASH FLOW
-12.28%
-62.8 M INVESTING CASH FLOW
-261766.67%
660 M FINANCING CASH FLOW
7300.21%
2.98 M REVENUE
-76.68%
-68.9 M OPERATING INCOME
-59.44%
-39.5 M NET INCOME
100.00%
-36.5 M OPERATING CASH FLOW
2.70%
2.86 M INVESTING CASH FLOW
104.59%
6.52 M FINANCING CASH FLOW
-98.57%
Balance Sheet NewAmsterdam Pharma Company N.V.
image
Current Assets 863 M
Cash & Short-Term Investments 834 M
Receivables 21.3 M
Other Current Assets 7.92 M
Non-Current Assets 1.21 M
Long-Term Investments 0
PP&E 673 K
Other Non-Current Assets 534 K
96.48 %Total Assets$864.6m
Current Liabilities 107 M
Accounts Payable 4.74 M
Short-Term Debt 246 K
Other Current Liabilities 102 M
Non-Current Liabilities 202 K
Long-Term Debt 202 K
Other Non-Current Liabilities 0
4.43 %95.15 %Total Liabilities$107.1m
EFFICIENCY
Earnings Waterfall NewAmsterdam Pharma Company N.V.
image
Revenue 45.6 M
Cost Of Revenue 0
Gross Profit 45.6 M
Operating Expenses 222 M
Operating Income -176 M
Other Expenses 65.3 M
Net Income -242 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)46m046m(222m)(176m)(65m)(242m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-386.91% OPERATING MARGIN
-386.91%
-530.25% NET MARGIN
-530.25%
-31.89% ROE
-31.89%
-27.94% ROA
-27.94%
-23.26% ROIC
-23.26%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NewAmsterdam Pharma Company N.V.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)20212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024Jul '24Jul '2420252025
Net Income -242 M
Depreciation & Amortization 113 K
Capital Expenditures -672 K
Stock-Based Compensation 33.6 M
Change in Working Capital -32.7 M
Others 62.2 M
Free Cash Flow -159 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NewAmsterdam Pharma Company N.V.
image
NAMSW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 3
6. Ownership
Insider Ownership NewAmsterdam Pharma Company N.V.
image
Sold
0-3 MONTHS
5.86 M USD 1
3-6 MONTHS
14.6 M USD 4
6-9 MONTHS
30 M USD 1
9-12 MONTHS
707 K USD 1
Bought
237 K USD 1
0-3 MONTHS
110 K USD 1
3-6 MONTHS
163 USD 1
6-9 MONTHS
98.7 K USD 2
9-12 MONTHS
7. News
8. Profile Summary

NewAmsterdam Pharma Company N.V. NAMSW

image
COUNTRY NL
INDUSTRY Biotechnology
MARKET CAP $ 3.18 B
Dividend Yield 0.00%
Description NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Contact Gooimeer 2-35, Naarden, 1411 DC https://www.newamsterdampharma.com
IPO Date Feb. 10, 2021
Employees 68
Officers Mr. Douglas F. Kling Chief Operating Officer Ms. Louise Kooij Chief Accounting Officer Dr. Michael Harvey Davidson FACC, Facp., M.D. Chief Executive Officer, President, Executive Board Member & Director Ms. Juliette Audet M.B.A., M.Sc. Chief Strategy & Business Officer Mr. Bob Rambo Executive Vice President of Marketing Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. Founder, Chief Scientific Officer, Member of Executive Board & Director Mr. Matthew Philippe Executive Vice President &Head of Investor Relations Ms. Maryellen McQuade Chief People Officer Dr. Marc Ditmarsch M.D. Chief Development Officer Mr. Mayur Amrat Somaiya Chief Financial Officer